CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast | |
Q2 Fiscal Year 2025 Results Press Release | 02/13/2025 at 7:30 a.m. ET |
Q2 Fiscal Year 2025 Conference Call-Live | 02/13/2025 at 11:00 a.m. ET |
US Toll Free Dial-In Number: | 1-888-506-0062 |
International Dial-In Number: | 1-973-528-0011 |
Participant Access Code: | 882092 |
Q2 Fiscal Year 2025 Conference Call-Replay | 02/13/2025-02/27/2025 |
US Toll Free Dial-In Number: | 1-877-481-4010 |
International Dial-In Number: | 1-919-882-2331 |
Participant Access Code: | 52016 |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
Last Trade: | US$0.76 |
Daily Change: | -0.009 -1.17 |
Daily Volume: | 169,747 |
Market Cap: | US$17.760M |
February 13, 2025 February 07, 2025 February 06, 2025 December 19, 2024 December 16, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load